Distribuzione geografica
Continente #
NA - Nord America 467
EU - Europa 225
AS - Asia 34
AF - Africa 1
Continente sconosciuto - Info sul continente non disponibili 1
Totale 728
Nazione #
US - Stati Uniti d'America 461
IT - Italia 65
DE - Germania 61
FR - Francia 29
IN - India 25
GB - Regno Unito 18
UA - Ucraina 15
SE - Svezia 9
BG - Bulgaria 8
IE - Irlanda 8
CA - Canada 6
CN - Cina 5
FI - Finlandia 5
ES - Italia 2
SG - Singapore 2
BE - Belgio 1
DZ - Algeria 1
EU - Europa 1
HK - Hong Kong 1
ID - Indonesia 1
LT - Lituania 1
NL - Olanda 1
PL - Polonia 1
RO - Romania 1
Totale 728
Città #
Chandler 150
Lawrence 32
Napoli 31
Millbury 26
Boston 19
Wilmington 19
Des Moines 16
Menlo Park 15
Ashburn 14
Krefeld 12
Fairfield 11
Houston 10
Woodbridge 9
Seattle 8
Sofia 8
Naples 7
Helsinki 5
Fremont 4
Redwood City 4
Roccasecca 3
Rottweil 3
Council Bluffs 2
Dublin 2
Milan 2
Milazzo 2
San Diego 2
Véry 2
Algiers 1
Augusta 1
Battipaglia 1
Birmingham 1
Borås 1
Brussels 1
Bucharest 1
Cambridge 1
Central 1
Duncan 1
Elora 1
Ferrol 1
Folignano 1
Giugliano in Campania 1
Guangzhou 1
Hangzhou 1
Hutchinson 1
Hyderabad 1
Jakarta 1
Las Palmas 1
Magenta 1
New Orleans 1
Norwalk 1
Ottawa 1
Quartu Sant'elena 1
Valle 1
Vancouver 1
Vilnius 1
Warsaw 1
Wuhan 1
Totale 448
Nome #
An indolent nasal form of primary cutaneous CD8-positive peripheral T-cell lymphoma not otherwise specified successfully treated with local radiation therapy- a new subtype? 69
Teledermatology and Inflammatory Skin Conditions during COVID-19 Era: New Perspectives and Applications 64
Drug safety evaluation of tildrakizumab for psoriasis: a review of the current knowledge 56
A new dermoscopic pattern for chilblain-COVID-19–like skin lesions in adolescents 37
Bimekizumab for the Treatment of Psoriasis: A Review of the Current Knowledge 28
Anti‐interleukin‐23 for psoriasis in elderly: guselkumab, risankizumab and tildrakizumab in real world practice 27
Erythrodermic Pityriasis Rubra Pilaris treatment: two case reports and literature review 25
Apremilast efficacy and safety in elderly psoriasis patients over a 48-weeks period 24
Biologic Therapies, Psoriasis, and COVID-19: Our Experience at the Psoriasis Unit of the University of Naples Federico II 24
Calcipotriol/betamethasone dipropionate formulations for psoriasis: an overview of the options and efficacy data 22
Generalized violaceous maculopapular rash and multiple verrucous nodules on the testes: a case of secondary syphilis misdiagnosed as lymphoma 22
Risankizumab in real life: preliminary results of efficacy and safety in psoriasis during a 16-week period 21
Guselkumab is efficacious and safe in psoriasis patients who failed anti-IL17: a 52-week real-life study 20
Hereditary Angioedema Type III, Recurrent Pregnancy Loss and Heterozygous MTHFR Mutation 19
A case of erythrodermic psoriasis successfully treated with guselkumab 18
Adalimumab in the Management of Isotretinoin-Induced Acne Fulminans: Report of a Case 18
Risankizumab treatment in psoriasis patients who failed anti-IL17: a 52-week real-life study 18
Real life efficacy and safety of secukinumab in elderly psoriasis patients over a 2-year period 16
A case of pediatric psoriasis successfully and rapidly treated with ixekizumab 16
Ciprofloxacin-induced symmetrical drug-related intertriginous and flexural exanthema (SDRIFE) in a psoriasis patient 16
Letter to the editor regarding article "Yalici-Armagan B, Tabak GH, Dogan-Gunaydin S, Gulseren D, Akdogan N, Atakan N. Treatment of psoriasis with biologics in the early COVID-19 pandemic: A study examining patient attitudes toward the treatment and disease course. J Cosmet Dermatol. 2021;00:1-5" 16
A case of erythrodermic psoriasis successfully treated with apremilast 16
Ixekizumab and brodalumab indirect comparison in the treatment of moderate to severe psoriasis: results from an Italian single-centre retrospective study in a real-life setting 15
Dermatophytid evaluated by in vivo reflectance confocal microscopy: a new approach? 15
Efficacy and Safety of Anti-TNF Biosimilars for Psoriasis in Pediatric and Geriatric Populations: A 72-Week Real-Life Study 14
A case of severe psoriatic arthritis with hands flexion contracture and palmar psoriasis successfully treated with guselkumab 14
Guselkumab in moderate to severe psoriasis in routine clinical care: an Italian 44-week real-life experience 14
Nail changes as manifestation of systemic disease in COVID‐19 infection 13
Reply to ‘New‐onset cutaneous lichen planus triggered by COVID‐19 vaccination’ by Merhy et al 13
Adalimumab biosimilar in a pediatric patient: clinical and in vivo reflectance confocal microscopy evaluation 12
Reply to "Where are the older adults? Age distribution of nail psoriasis-randomized clinical trials' participants: a systematic review" by Ricardo JW et al 11
Therapeutic update of biologics and small molecules for scalp psoriasis: a systematic review 10
Immune response to Covid‐19 mRNA vaccination in psoriasis patients undergoing treatment with biologics 10
The impact of COVID ‐19 infection on psoriatic patients treated with biologics: an Italian experience 9
New frontiers in personalized medicine in psoriasis 9
Secukinumab: a potential safe option in psoriasis patients affected by multiple sclerosis? 9
Tildrakizumab for the treatment of moderate to severe psoriasis: results from a single center preliminary real‐life study 7
Teledermatology: a useful tool also after Covid-19 era? 7
Letter to the editor regarding article "Oguz Topal I, Kara Polat A, Zindancı İ, et al. Adherence to systemic therapy in patients with psoriasis during the COVID-19 pandemic: A multicenter study. J Cosmet Dermatol. 2021;10.1111/jocd.14610." 6
Reply to "Routine re-screening for latent tuberculosis has low utility in patients with chronic immune-mediated inflammatory diseases treated with biologics: a single-center retrospective cohort study" 6
A Case of Adult-onset Facial Cutaneous Mastocytoma: Clinical and Dermoscopic Findings 5
Topical oil formulation of plant extracts and vitamins as effective treatment for stretch marks and xerosis—An observational longitudinal study 5
Treating psoriasis in the elderly: biologics and small molecules 5
Reply to “A case of symmetrical drug‐related intertriginous and flexural exanthema‐like eruption associated with Pfizer COVID ‐19 vaccination” by Manaa et al 4
Treatment of pediatric psoriasis with TNF-antagonists: a real-life single-center case series 4
Efficacy and safety of biologics and small molecules for psoriasis in pediatric and geriatric populations. Part I: focus on pediatric patients 4
Efficacy and safety of biologics and small molecules for psoriasis in pediatric and geriatric populations. Part II: focus on elderly patients 3
Towards Personalized Medicine in Psoriasis: Current Progress 3
Ixekizumab in scalp psoriasis: Clinical, dermoscopical, and in vivo reflectance confocal microscopy evaluation 3
Paradoxical reactions to biologicals for psoriasis 1
Totale 823
Categoria #
all - tutte 2120
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 2120

Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202020 0000 00 01 12106
2020/2021151 2421 710 245 62880
2021/2022277 17014 156 817 63412481
2022/2023375 37351517 3956 4964 63000
Totale 823